RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
81 hedge funds and large institutions have $404M invested in RAPT Therapeutics in 2020 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 24 increasing their positions, 16 reducing their positions, and 17 closing their positions.
125% more funds holding in top 10
Funds holding in top 10: 4 → 9 (+5)
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
50% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 16
21% more funds holding
Funds holding: 67 → 81 (+14)
1.82% more ownership
Funds ownership: 8.6% → 10.41% (+1.8%)
19% less call options, than puts
Call options by funds: $2.51M | Put options by funds: $3.08M
25% less capital invested
Capital invested by funds: $542M → $404M (-$138M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$42.9M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$6.89M |
| 3 |
BlackRock
New York
|
+$5.29M |
| 4 |
Millennium Management
New York
|
+$4.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$18.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.4M |
| 3 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$7.03M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$3.7M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.56M |
RAPT Hedge Fund Activity: Q4 2020 in Review
81 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2020, worth a combined $404M — down 25% from $542M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new RAPT positions and 17 closed out — a net gain of 16 holders — while 24 added to existing stakes and 16 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $42.9M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $18.5M sold.
- 81 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2020, up from 67 in Q3 2020.
- Funds reported $404M of RAPT Therapeutics stock for Q4 2020, down 25% quarter-over-quarter.
- 33 funds opened new RAPT Therapeutics positions in Q4 2020 and 17 closed out, a net change of +16 holders.
- The largest RAPT Therapeutics buyer in Q4 2020 was Perceptive Advisors, an estimated $42.9M added.
- The largest RAPT Therapeutics seller in Q4 2020 was Avoro Capital Advisors, an estimated $18.5M sold.
Based on aggregated 13F filings for Q4 2020.